The **HIM Act**, formally known as the **Prostate-Specific Antigen (PSA) Screening for High-risk Insured Men Act**, aims to improve early detection of prostate cancer by making PSA screenings more accessible[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1"). Here are some key points about the HIM Act:

- **Purpose**: The HIM Act requires group health plans and health insurance issuers to provide coverage for prostate cancer screenings without imposing cost-sharing requirements (such as copays, deductibles, or coinsurance) for high-risk individuals[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1").

- **High-Risk Groups**: The Act focuses on African-American men and men with a family history of prostate cancer, as these groups are at a higher risk of developing prostate cancer[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1").

- **Importance of PSA Tests**: PSA tests are crucial for detecting prostate cancer early, which significantly improves survival rates[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1"). Early-stage prostate cancer has a near 100% survival rate, while late-stage prostate cancer has a much lower survival rate[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1").

- **Legislative Status**: The HIM Act has been introduced in both the House (H.R. 1826) and the Senate (S. 2821)[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1"). It is currently under review by the respective committees[](https://www.congress.gov/bill/118th-congress/house-bill/1826/text "2").

The HIM Act is designed to remove financial barriers to PSA screenings, ensuring that more men can access this life-saving test without worrying about the cosThe **HIM Act**, formally known as the **Prostate-Specific Antigen (PSA) Screening for High-risk Insured Men Act**, aims to improve early detection of prostate cancer by making PSA screenings more accessible[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1"). Here are some key points about the HIM Act:

- **Purpose**: The HIM Act requires group health plans and health insurance issuers to provide coverage for prostate cancer screenings without imposing cost-sharing requirements (such as copays, deductibles, or coinsurance) for high-risk individuals[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1").

- **High-Risk Groups**: The Act focuses on African-American men and men with a family history of prostate cancer, as these groups are at a higher risk of developing prostate cancer[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1").

- **Importance of PSA Tests**: PSA tests are crucial for detecting prostate cancer early, which significantly improves survival rates[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1"). Early-stage prostate cancer has a near 100% survival rate, while late-stage prostate cancer has a much lower survival rate[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1").

- **Legislative Status**: The HIM Act has been introduced in both the House (H.R. 1826) and the Senate (S. 2821)[](https://zerocancer.org/educational-materials/overview-psa-screening-him-act "1"). It is currently under review by the respective committees[](https://www.congress.gov/bill/118th-congress/house-bill/1826/text "2").

The HIM Act is designed to remove financial barriers to PSA screenings, ensuring that more men can access this life-saving test without worrying about the costext.